Tunable Anticoagulation via Co-Aggregating SARS-CoV-2 Peptides (presented at the 25th UP-PGH S&T Week)

This study introduces a method for tunable anticoagulation using the interaction between specific SARS-CoV-2 peptide analogs. By leveraging the co-aggregation properties of viral sequences, we demonstrate a mechanism to modulate blood clotting through the sequestration of heat-labile coagulation factors.Key Technical Highlights:Mechanism of Action: Utilization of peptide N155 to induce anticoagulation via interaction with essential coagulation factors.Aggregation Dynamics: Computational prediction of self-aggregation (-10.07 kcal/mol) and co-aggregation (-4.65 kcal/mol) between peptides N155 and 8A.Precision Control: Demonstration of a "tunable" response by adjusting the N155-8A molar ratio from 1:0.55 to 1:2.2, allowing for precise titration between procoagulation and anticoagulation states.Therapeutic Potential: Insights into the development of anticoagulants and potential treatments for coagulopathy associated with viral infections.This research provides a proof-of-concept for biomaterials that can safely manage hemostasis using sequence-specific peptide interactions.